Petosemtamab
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb) . Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) [1][2].
Product Specifications
CAS Number
2213450-26-9
Product Name Alternative
MCLA 158
UNSPSC
12352203
Target
EGFR
Type
Inhibitory Antibodies
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/petosemtamab.html
Purity
99.94
Solubility
10 mM in DMSO
Smiles
[Petosemtamab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Antoine Hollebecque, et al. Abstract P185: Preliminary antitumor activity of MCLA-158, an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma. Mol Cancer Ther (2021) 20 (12_Supplement) : P185.|[2]Guillem Argiles, et al. Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC) . Journal of Clinical Oncology 39, no. 3_suppl
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
EGFR/ErbB1/HER1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![CDKL2 Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI1D1]](https://cdn.genprice.uk/products/937/68dd1b7c061270361ea1ca4e/imageurl/ta805535am.webp)
TA805535AM 100 µL
CDKL2 Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI1D1]
Sign In for Pricing
View Details 
9122 1 Each
Far-Red Fluorescent FLICA® 660 Caspase-1 (YVAD) Assay Kit
Sign In for Pricing
View Details 
KN420350 1 Kit
Cytokeratin 4 (KRT4) Human Gene Knockout Kit (CRISPR)
Sign In for Pricing
View Details 